Morgan Stanley: WuXi XDC (02268.HK) reiterates full-year revenue growth target of 40%; maintains "Overweight" rating.

Zhitong Finance APP has learned that Morgan Stanley issued a research report stating that the management of WuXi XDC (02268.HK) reiterated its full-year revenue growth target of 40% at constant exchange rates, including the contribution from BioDlink. The bank maintained its "Overweight" rating and target price of HK$85 for the company.